Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of cabozantinib in advanced salivary gland cancer
NL-OMON46770Phase 2Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cabozantinib in salivary gland cancer (SGC) (3 cohorts), sponsored by Radboud University Medical Center. Primary endpoint: Objective response rate. Started Sep 2018; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on NL-OMON46770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46770.